Literature DB >> 3373302

Kinetic analysis and probability mapping applied to the detection of ovarian cancer by radioimmunoscintigraphy.

M Granowska1, C C Nimmon, K E Britton, M Crowther, S J Mather, M L Slevin, J H Shepherd.   

Abstract

Kinetic analysis with probability mapping is an objective method of serial image analysis applicable to radioimmunoscintigraphy. The technique is described and subjected to clinical testing by comparing the prediction of biopsy histology from the probability map in patients coming to operation. In those with ovarian cancer undergoing second-look laparotomy after completing full courses of chemotherapy, the prediction of histology in 108 biopsy sites was 45 true positives and 38 true negatives, sensitivity 80%, specificity 73%, accuracy 77% p less than 0.001. In patients with tumors less than 2 cm diameter, 41 biopsy sites were predicted with a specificity of 78% and an accuracy of 76%, p less than 0.01. The technique is reducing the need for second-look laparotomy in patients with subclinical and subradiological disease. Such disease is suitable for intraperitoneal radioimmunotherapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3373302

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

1.  Evaluation of therapeutic response using iodine-131-B72.3 monoclonal antibody in patients with ovarian carcinoma.

Authors:  L Camera; S Del Vecchio; A Petrillo; G Esposito; G Frasci; R V Iaffaioli; A R Bianco; M Salvatore
Journal:  Eur J Nucl Med       Date:  1991

Review 2.  The present and future of radiolabelled antibodies in oncology.

Authors:  K E Britton; M Granowska
Journal:  Ann Nucl Med       Date:  1993-08       Impact factor: 2.668

3.  Radioimmunoscintigraphy with technetium-99m labelled monoclonal antibody, 1A3, in colorectal cancer.

Authors:  M Granowska; K E Britton; S J Mather; G Morris; D Ellison; S Soobramoney; I C Talbot; J M Northover
Journal:  Eur J Nucl Med       Date:  1993-08

4.  Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer.

Authors:  M Granowska; K E Britton; S J Mather; D G Lowe; D Ellison; J Bomanji; J Burchell; J Taylor-Papadimitriou; C R Hudson; J H Shepherd
Journal:  Eur J Nucl Med       Date:  1993-06

5.  Inhibition of the hepatocyte uptake of radiolabelled monoclonal antibodies by chelating agents.

Authors:  B R Davidson; P B Boulos; J B Porter
Journal:  Eur J Nucl Med       Date:  1990

6.  99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection.

Authors:  L Biassoni; M Granowska; M J Carroll; S J Mather; R Howell; D Ellison; F A MacNeill; C A Wells; R Carpenter; K E Britton
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

7.  Axillary node status in breast cancer patients prior to surgery by imaging with Tc-99m humanised anti-PEM monoclonal antibody, hHMFG1.

Authors:  A R Al-Yasi; M J Carroll; D Ellison; M Granowska; S J Mather; C A Wells; R Carpenter; K E Britton
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.